Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

HeartSciences (HSCS) EBITDA Margin (2021 - 2025)

HeartSciences' EBITDA Margin history spans 5 years, with the latest figure at 85713.23% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 8740121.0% year-over-year to 85713.23%; the TTM value through Jan 2026 reached 89939.57%, down 9587143.0%, while the annual FY2025 figure was 192013.13%, 15811114.0% down from the prior year.
  • EBITDA Margin reached 85713.23% in Q4 2025 per HSCS's latest filing, up from 98637.84% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 9214.54% in Q3 2024 to a low of 98637.84% in Q3 2025.
  • Average EBITDA Margin over 5 years is 36402.29%, with a median of 40254.95% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: soared 5676700bps in 2024, then plummeted -10785238bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 9011.84% in 2021, then crashed by -396bps to 44690.53% in 2022, then grew by 10bps to 40254.95% in 2023, then surged by 104bps to 1687.98% in 2024, then plummeted by -5178bps to 85713.23% in 2025.
  • Per Business Quant, the three most recent readings for HSCS's EBITDA Margin are 85713.23% (Q4 2025), 98637.84% (Q3 2025), and 44147.1% (Q2 2025).